My watch list
my.bionity.com  
Login  

The antibody bevacizumab (Avastin) has been used clinically to treat intraocular neovascular diseases based on its antivascular endothelial growth factor (VEGF) character. The anti-VEGF strategy for retinal neovascular diseases is limited by the short half-life of bevacizumab and thus requires frequent injections. This Article reports the sustained release of bevacizumab from a biocompatible material that is composed of a triblock copolymer of poly(2-ethyl-2-oxazoline)-b-poly(ε-caprolactone)-b-poly(2-ethyl-2-oxazoline) (PEOz-PCL-PEOz). The amphiphilic PEOz-PCL-PEOz triblock copolymer was synthesized in three steps. First, the PEOz was polymerized by methyl p-toluenesulfonate and 2-ethyl-2-oxazoline (EOz), and the living end was terminated by potassium hydroxide methanolic solution. Subsequently, the hydroxyl-PEOz was used as a macroinitiator for the ring-opening polymerization of ε-caprolactone using a Tin(II) octoate catalyst to synthesize the telechelic hydroxylated PEOz-PCL. Finally, the PEOz-PCL-PEOz ...

Authors:   Chau-Hui Wang; Yih-Shiou Hwang; Ping-Ray Chiang; Chia-Rui Shen; Wei-Hsin Hong; Ging-Ho Hsiue
Journal:   Biomacromolecules
Year:   2011
DOI:   10.1021/bm2009558
Publication date:   22-12-2011

Watchlist

This is where you can add this publication to your personal favourites.

Additional Information

Facts, background information, dossiers
More about American Chemical Society Publications
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE